XML 15 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
Condensed Consolidated Statements of Changes in Stockholders’ Equity - USD ($)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity
Non-Controlling Interest
Total
Balance at Sep. 30, 2023 $ 6,354 $ 253,056,133 $ (162,231,379) $ 90,831,108 $ 600,380 $ 91,431,488
Balance (in Shares) at Sep. 30, 2023   6,354,371          
Issuance of common stock for services $ 4 76,142 76,146 76,146
Issuance of common stock for services (in Shares)   4,351          
Stock-based compensation expense 3,058,185 3,058,185 3,058,185
Net loss (9,231,185) (9,231,185) (9,231,185)
Balance at Dec. 31, 2023 $ 6,358 256,190,460 (171,462,564) 84,734,254 600,380 85,334,634
Balance (in Shares) at Dec. 31, 2023   6,358,722          
Balance at Sep. 30, 2024 $ 7,247 271,440,421 (201,370,218) 70,077,450 4,024,380 74,101,830
Balance (in Shares) at Sep. 30, 2024   7,247,243          
Issuance of common stock, net of costs $ 480 2,573,571 2,574,051 2,574,051
Issuance of common stock, net of costs (in Shares)   480,000          
Stock-based compensation expense 2,524,824 2,524,824 2,524,824
Net loss (10,281,246) (10,281,246) (10,281,246)
Net loss attributable to non-controlling interest 513,000 513,000 (513,000)
Balance at Dec. 31, 2024 $ 7,727 $ 276,538,816 $ (211,138,464) $ 65,408,079 $ 3,511,380 $ 68,919,459
Balance (in Shares) at Dec. 31, 2024   7,727,243